Earlier this morning NNVC issued a press release announcing that, "...Renowned Japanese ophthalmologist and corneal researcher, Kazuo Tsubota, MD, PhD, has agreed to join the Company’s Scientific Advisory Board."
The press release also slipped in this little tidbit:
“I have already had licensing discussions with Japanese pharmaceutical companies regarding EkcCide™,” said Dr. Tsubota, adding, “There has been significant interest in Japan in the excellent animal study results from the Institute in New York.”What I find so intriguing is that in a press release dated June 30, 2008, NNVC announced that this same Dr. Tsubota, "...Has agreed to perform confirmatory animal efficacy studies of the nanoviricide anti-EKC drug candidate, EKC–Cide™, against EKC (epidemic kerato-conjunctivitis) in Japan."
“Dr. Tsubota will be helping us prepare the Company’s nanoviricides drug candidates to enter the regulatory approval process in Japan. Initially, he will focus on viral eye diseases such as EKC and Herpes virus infection, among others,” said Eugene Seymour, MD, MPH, CEO of the Company.
In between these two releases there has been no news as to how that confirmatory testing in Japan was going. Yet the renowned Japanese ophthalmologist, Dr. Tsubota, has not only agreed to become a member of NNVC's Scientific Advisory Board, he is, according to the press release out today, already, "...In licensing discussions with with Japanese pharmaceutical companies regarding EkcCide.™"
What can be gleaned from all of this? Whatever Dr. Tsubota has seen in his review of EkcCide™ has impressed him and is significant enough that Dr. Tsubota wants to be part of Nanoviricides and wants to represent the Company in Japan.
In due time, all of this will make better sense, as whatever pieces of this puzzle may be missing, they can only mean good things of NNVC.